RU2006120484A - Микрочастицы, содержащие аналоги соматостатина - Google Patents
Микрочастицы, содержащие аналоги соматостатина Download PDFInfo
- Publication number
- RU2006120484A RU2006120484A RU2006120484/15A RU2006120484A RU2006120484A RU 2006120484 A RU2006120484 A RU 2006120484A RU 2006120484/15 A RU2006120484/15 A RU 2006120484/15A RU 2006120484 A RU2006120484 A RU 2006120484A RU 2006120484 A RU2006120484 A RU 2006120484A
- Authority
- RU
- Russia
- Prior art keywords
- microparticles according
- microparticles
- composition according
- salt
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
Claims (13)
1. Микрочастицы, включающие аналог соматостатина, включающий последовательность аминокислот формулы I
в которой X1 обозначает радикал формулы (а) или (б)
в которой R1 представляет собой необязательно замещенный фенил, R2 обозначает -Z1-CH2-R1, -CH2-CO-O-CH2-R1,
где Z1 обозначает О или S, и
Х2 представляет собой α-аминокислоту, имеющую ароматический остаток на Сα-боковой цепи или аминокислотную группу, выбранную из Dab, Dpr, Dpm, His, (Bzl)HyPro, тиенил-Ala, циклогексил-Ala и трет-бутил-А1а, причем остаток Lys указанной последовательности соответствует остатку Lys9 нативного соматостатина-14
в свободной форме, в форме соли или защищенной форме,
погруженный в полимерную матрицу.
2. Микрочастицы по п.1, в которых аналог соматостатина представляет собой соединение формулы III
в которой конфигурация в положении С-2 представляет собой (R) или (S) или их смесь и
в которой R обозначает NR1R2-C2-6алкилен или гуанидин-С2-6алкилен и каждый из R1 и R2 независимо друг от друга обозначают Н или С1-4алкил, в свободной форме, в форме соли или защищенной форме.
3. Микрочастицы по п.2, в которых аналог соматостатина находится в форме соли памовой кислоты.
4. Микрочастицы по п.3, в которых полимерная матрица включает линейный или разветвленный полилактид-со-гликолид.
5. Микрочастицы по п.4, в которых полимерная матрица включает по меньшей мере два различных полимера.
6. Микрочастицы по п.4, дополнительно включающие поверхностно-активное вещество, агент, влияющий на пористость, и/или основную соль.
7. Фармацевтическая композиция, включающая микрочастицы по любому из предшествующих пунктов и носитель на водной основе, включающий смачивающий агент.
8. Композиция по п.7, в которой смачивающий агент включает полоксамер и/или полиоксиэтиленовый эфир сорбитана и жирной кислоты.
9. Композиция по любому из пп.7 или 8, в которой носитель включает агент тоничности.
10. Композиция по любому из пп.7 или 8, в которой носитель включает агент, повышающий вязкость.
11. Набор, включающий микрочастицы по любому из пп.1-6 и носитель на водной основе.
12. Применение микрочастиц по любому из пп.1-6 или фармацевтической композиции по любому из пп.7-10 для приготовления лекарственного препарата для лечения заболевания или нарушения с этиологией, включающей или ассоциированной с избыточной секрецией GH и/или IGF-1.
13. Способ лечения заболевания или нарушения с этиологией, включающей или ассоциированной с избыточной секрецией GH и/или IGF-1 нуждающегося в этом субъекта, включающий введение субъекту микрочастиц по любому из пп.1-6 или фармацевтической композиции по любому из пп.7-10.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0326602.0 | 2003-11-14 | ||
GB0326602A GB0326602D0 (en) | 2003-11-14 | 2003-11-14 | Organic compounds |
GB0406241.0 | 2004-03-19 | ||
GB0406241A GB0406241D0 (en) | 2004-03-19 | 2004-03-19 | Organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006120484A true RU2006120484A (ru) | 2007-12-27 |
RU2404749C2 RU2404749C2 (ru) | 2010-11-27 |
Family
ID=34593737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006120484/15A RU2404749C2 (ru) | 2003-11-14 | 2004-11-12 | Микрочастицы, содержащие аналоги соматостатина |
Country Status (31)
Country | Link |
---|---|
US (3) | US7759308B2 (ru) |
EP (1) | EP1686964B9 (ru) |
JP (1) | JP4682145B2 (ru) |
KR (1) | KR101233892B1 (ru) |
AR (1) | AR047310A1 (ru) |
AT (1) | ATE455537T1 (ru) |
AU (1) | AU2004289055C1 (ru) |
BR (1) | BRPI0416227B8 (ru) |
CA (1) | CA2541944C (ru) |
CY (2) | CY1110293T1 (ru) |
DE (1) | DE602004025271D1 (ru) |
DK (1) | DK1686964T3 (ru) |
EC (1) | ECSP066565A (ru) |
ES (1) | ES2339026T3 (ru) |
HK (1) | HK1093682A1 (ru) |
HR (1) | HRP20100190T1 (ru) |
IL (1) | IL175286A (ru) |
IS (1) | IS8480A (ru) |
LU (1) | LU92701I2 (ru) |
MA (1) | MA28155A1 (ru) |
MX (1) | MXPA06005357A (ru) |
MY (1) | MY158342A (ru) |
NO (2) | NO337172B1 (ru) |
NZ (1) | NZ546788A (ru) |
PE (1) | PE20050581A1 (ru) |
PL (1) | PL1686964T3 (ru) |
PT (1) | PT1686964E (ru) |
RU (1) | RU2404749C2 (ru) |
SI (1) | SI1686964T1 (ru) |
TW (1) | TWI295178B (ru) |
WO (1) | WO2005046645A1 (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
PT1968549E (pt) * | 2005-12-22 | 2014-08-29 | Novartis Ag | Formulação de libertação controlada compreendendo octreotida e dois ou mais polímeros de polilactídeo-co-glicolídeo |
KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
AR066677A1 (es) * | 2007-05-24 | 2009-09-02 | Novartis Ag | Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas. |
WO2009095450A1 (en) * | 2008-01-30 | 2009-08-06 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
CA2716010C (en) * | 2008-04-03 | 2019-10-01 | Zymogenetics, Inc. | Hemostatic microspheres |
US9314508B2 (en) * | 2008-07-08 | 2016-04-19 | Novartis Ag | Use of somatostatin analogs in control of hypoglycemia |
US20100151033A1 (en) * | 2008-12-15 | 2010-06-17 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
US8815971B2 (en) | 2008-12-22 | 2014-08-26 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US8822610B2 (en) | 2008-12-22 | 2014-09-02 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
WO2010123574A1 (en) | 2009-04-23 | 2010-10-28 | Atrp Solutions Inc | Star macromolecules for personal and home care |
US9783628B2 (en) | 2009-04-23 | 2017-10-10 | ATRP Solutions, Inc. | Dual-mechanism thickening agents for hydraulic fracturing fluids |
US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
WO2014036498A2 (en) | 2012-08-30 | 2014-03-06 | ATRP Solutions, Inc. | Dual mechanism thickening agents for hydraulic fracturing fluids |
WO2014121188A1 (en) | 2013-02-04 | 2014-08-07 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
US9587064B2 (en) | 2010-12-08 | 2017-03-07 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
WO2013131879A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | New application for pasireotide |
JP2016512523A (ja) | 2013-03-11 | 2016-04-28 | デュレクト コーポレーション | 高粘性液体キャリアを含む注射用制御放出組成物 |
TW201605488A (zh) * | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及/或治療多囊腎病之藥物 |
US10336848B2 (en) | 2014-07-03 | 2019-07-02 | Pilot Polymer Technologies, Inc. | Surfactant-compatible star macromolecules |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
AU5678398A (en) | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
EP1240896A3 (en) | 1998-07-23 | 2003-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Encapsulation of water soluble peptides |
WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
AU4964699A (en) * | 1998-07-23 | 2000-02-14 | Biomeasure Incorporated | Encapsulation of water soluble peptides |
JP4303438B2 (ja) | 1999-08-18 | 2009-07-29 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | ペプチドの持続放出製剤 |
GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
AU2003221497A1 (en) * | 2002-03-13 | 2003-09-22 | Novartis Ag | Pharmaceutical microparticles |
MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
-
2004
- 2004-11-09 MY MYPI20044662A patent/MY158342A/en unknown
- 2004-11-11 AR ARP040104157A patent/AR047310A1/es not_active Application Discontinuation
- 2004-11-12 DE DE602004025271T patent/DE602004025271D1/de active Active
- 2004-11-12 KR KR1020067009270A patent/KR101233892B1/ko active IP Right Grant
- 2004-11-12 DK DK04797866.3T patent/DK1686964T3/da active
- 2004-11-12 TW TW093134728A patent/TWI295178B/zh active
- 2004-11-12 US US10/579,186 patent/US7759308B2/en active Active
- 2004-11-12 JP JP2006538808A patent/JP4682145B2/ja active Active
- 2004-11-12 PL PL04797866T patent/PL1686964T3/pl unknown
- 2004-11-12 ES ES04797866T patent/ES2339026T3/es active Active
- 2004-11-12 PT PT04797866T patent/PT1686964E/pt unknown
- 2004-11-12 BR BRPI0416227A patent/BRPI0416227B8/pt active IP Right Grant
- 2004-11-12 AT AT04797866T patent/ATE455537T1/de active
- 2004-11-12 NZ NZ546788A patent/NZ546788A/en unknown
- 2004-11-12 PE PE2004001111A patent/PE20050581A1/es active IP Right Grant
- 2004-11-12 SI SI200431378T patent/SI1686964T1/sl unknown
- 2004-11-12 AU AU2004289055A patent/AU2004289055C1/en active Active
- 2004-11-12 WO PCT/EP2004/012870 patent/WO2005046645A1/en active Application Filing
- 2004-11-12 RU RU2006120484/15A patent/RU2404749C2/ru active
- 2004-11-12 EP EP04797866A patent/EP1686964B9/en active Active
- 2004-11-12 CA CA2541944A patent/CA2541944C/en active Active
- 2004-11-12 MX MXPA06005357A patent/MXPA06005357A/es active IP Right Grant
-
2006
- 2006-04-27 IL IL175286A patent/IL175286A/en active IP Right Grant
- 2006-05-11 MA MA29019A patent/MA28155A1/fr unknown
- 2006-05-12 EC EC2006006565A patent/ECSP066565A/es unknown
- 2006-05-23 IS IS8480A patent/IS8480A/is unknown
- 2006-06-14 NO NO20062777A patent/NO337172B1/no active Protection Beyond IP Right Term
-
2007
- 2007-01-04 HK HK07100155.4A patent/HK1093682A1/xx unknown
-
2010
- 2010-03-09 CY CY20101100222T patent/CY1110293T1/el unknown
- 2010-04-01 HR HR20100190T patent/HRP20100190T1/hr unknown
- 2010-06-08 US US12/796,132 patent/US8188037B2/en active Active
-
2012
- 2012-04-26 US US13/456,681 patent/US20120214749A1/en not_active Abandoned
-
2015
- 2015-03-26 CY CY2015011C patent/CY2015011I1/el unknown
- 2015-04-29 LU LU92701C patent/LU92701I2/xx unknown
-
2016
- 2016-02-02 NO NO2016003C patent/NO2016003I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006120484A (ru) | Микрочастицы, содержащие аналоги соматостатина | |
RU2208015C2 (ru) | Аналоги гпп-1 | |
AU726731B2 (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
RU2001118855A (ru) | Аналоги glp-1 | |
KR920700226A (ko) | 선형 소마토스타틴 유사체 | |
KR920702854A (ko) | 제6위치에 트레오닌을 가지고 있는 소마토 스타틴의 옥타펩티드 유사물 | |
JP4977622B2 (ja) | ビスホスホネート含有徐放性製剤 | |
CA2402191A1 (en) | Use of insulin for the treatment of cartilagenous disorders | |
RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
CZ2001331A3 (cs) | Pulmonální dodávání aktivních přípravků | |
RU2007131504A (ru) | Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r) | |
FI93308C (fi) | Menetelmä somatostatiinia sisältävän farmaseuttisen ainekoostumuksen valmistamiseksi | |
KR870000934A (ko) | 성장촉진 호르몬의 안정화 방법 | |
US5002771A (en) | Calcitonin suppository formulations | |
RU2009147217A (ru) | Новые противоопухолевые соединения | |
EP0351354A2 (en) | Somatostatin derivatives for the treatment of arthritis | |
RU2003129807A (ru) | Антагонисты соматостатина | |
RU2006115606A (ru) | Применение соматостатина или одного из его аналогов для приготовления лекарственного средства, которое предназначено для регуляции фолликулярного резерва яичников у женщин, у которых не наступила менопауза | |
RU2006101720A (ru) | Фармацевтическая композиция | |
RU2002101732A (ru) | Агонисты соматостатина | |
JP2004532824A5 (ru) | ||
RU2005115129A (ru) | Новые аналоги 2`, 5` -олигоаденилата | |
DE60237784D1 (de) | Verfahren zur verabreichung eines thymosin-alpha 1 peptids | |
US6342479B1 (en) | Prolonging survival of transplanted pancreatic cells | |
RU99106239A (ru) | Способ ингибирования фиброза агонистом соматостатина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20201014 |